Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
Strict, and sometimes arbitrary, clinical trial eligibility criteria are a key barrier to enrollment. A patient with a GFR of 52 being excluded from a trial requiring a GFR of 60 illustrates how minor, clinically insignificant differences can prevent patients from accessing novel therapies. This highlights a need for more pragmatic and flexible trial inclusion criteria.
Related Insights
The NIAGRA study used a creatinine clearance threshold of 40 ml/min for cisplatin, lower than the traditional 60 ml/min cutoff. This forward-looking design validates the practice of treating patients with borderline renal function with cisplatin, potentially allowing more individuals with MIBC to benefit from this chemotherapy.
The ASPIRE trial design was altered due to pushback from patient advocates who felt it was unethical to randomize metachronous low-volume disease patients to a chemotherapy arm. This led to the exclusion of that subgroup, demonstrating how advocate consensus can override a purely biology-based trial design in favor of perceived patient benefit.
The LEAP-010 trial excluded patients with vascular involvement due to the drug's bleeding risk. This is a common characteristic in real-world head and neck cancer patients, especially post-radiation. This discrepancy means that even if the drug combination had been successful, its applicability in routine clinical practice would be severely limited.
A primary obstacle preventing community SCLC patients from joining clinical trials is not their unwillingness, but physicians not offering the option due to assumptions about patient interest or eligibility. The first step to improving enrollment is ensuring the conversation happens.
When a highly effective therapy like EV Pembro was approved for 'cisplatin ineligible' patients, the definition of 'ineligible' became very elastic in practice. This demonstrates that when a new treatment is seen as transformative, clinicians find ways to qualify patients, putting pressure on established guidelines.
Clinical trials use arbitrary, time-based definitions (e.g., relapse within 2 years) for endocrine resistance. This isn't a perfect biological classification but a practical necessity to create homogeneous patient groups for testing, which may not fully reflect the diverse patient population in clinical practice.
The former high-risk group (Stage 3b) was traditionally excluded from major clinical trials. The new staging system demonstrates that these patients have better-than-expected outcomes with modern therapy and should be included in future studies. It simultaneously identifies a new ultra-high-risk group (Stage 3c) that requires entirely different trial designs.
Even when trials like LITESPARK 022 and Keynote 564 use identical eligibility criteria, outdated staging systems result in patient populations with different underlying risks. This makes direct comparison of outcomes between trials, even for the same drug, an unfair and statistically flawed analysis that ignores the function of a control arm.
For pancreatic cancer patients, the primary obstacle to receiving promising KRAS-targeted therapies is not drug efficacy but logistical access. There are far more eligible patients than available slots on clinical trials, creating a significant and "tragic" bottleneck in delivering cutting-edge care.
Dr. Richardson repeatedly emphasizes that modern clinical trial design must incorporate FDA guidance. Key elements now considered vital for approval include upfront dose optimization phases and deliberate inclusion of diverse populations, particularly African American patients, to ensure relevance and equity.
